The boy, who was aged between two and four, suffered a cardiac arrest after receiving the one-off gene therapy last year. It was poised to become one of the world's most expensive drugs. Read this story
The boy, who was aged between two and four, suffered a cardiac arrest after receiving the one-off gene therapy last year. It was poised to become one of the world's most expensive drugs. Read this story
More from dailym.ai | dailymail health FDA New York Pfizer